• TESARO, Roche to evaluate triplet therapy for ovarian cancer biospectrumasia
    June 07, 2018
    TESARO and Genentech are also working together to evaluate the combination of ZEJULA and atezolizumab in patients with metastatic bladder cancer as a part of MORPHEUS, Roche's novel cancer immunotherapy development platform.
PharmaSources Customer Service